Influence of early prehospital thrombolysis on mortality and event-free survival (The myocardial infarction triage and intervention [MITI]randomized trial) by Brouwer, M.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24122
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Influence of Early Prehospital 
Thrombolysis on Mortality and Event- 
Free Survival (The Myocardial Infarction
Triage and Intervention [MITI]
Randomized Trial)
t
Marc A. Brouwer, MD, Jenny S. Martin, RN, Charles Maynard, PhD, Mark Wirkus, BS, 
Paul E. Litwin, M S, Freek W .A. Verheugt, MD, and W . Douglas Weaver, MD, 
for the MITI Project Investigators
The Myocardial Infarction Triage and Intervention Trial 
of prehospital versus hospital administration of throm­
bolytic therapy markedly reduced hospital treatment 
times, but the 2 groups had similar outcomes* However, 
patients treated < 7 0  minutes from symptom onset had 
better short-term outcomes. The purpose of this study 
was to determine the long-term influence of very early 
thrombolytic treatment for acute myocardial infarction. 
A  total of 360 patients were followed for vital status and 
cardiac-related hospital admissions over a period of 34 
± 1 6  months. Patients enrolled in the trial had symptoms 
for ^ 6  hours, ST-segment elevation on the prehospital 
electrocardiogram, and no risk factors for serious bleed­
ing, They received aspirin and recombinant tissue plas­
minogen activator either before or after hospital arrival. 
Primary end points in this study included long-term sur­
vival and survival free of death or readmission to the 
hospital for angina, myocardial infarction, congestive 
heart failure, or revascularization. Two-year survival 
was 89% for prehospital- and 91% for hospital-treated 
patients (p = 0.46), Event-free survival at 2 years was 
56% and 64% for prehospital- and hospitahtreated pa­
tients, respectively (p =  0.42). In patients treated <70  
minutes from symptom onset, 2-year survival was 98%, 
and it was 88% for those treated later (p = 0.12). Two- 
year event-free survival was 65% for patients treated 
early and 59% for patients treated later (p = 0.80). In 
this trial, poorer long-term survival was associated with 
advanced age, history of congestive heart failure, and 
coronary artery bypass surgery performed before the 
index hospitalization, but not with time to treatment.
(Am i  Cardiol 1996;78:497-502)
thrombolytic therapy has been p roven  to reduce 
early mortality and to im prove 1 -year survival 
rates in patients w ith  acute m yocard ial infarction ,1" 7 
T he greatest m ortality  reduction is show n in patients 
w ho receive treatm ent w ith in  the first 1 to 2  hours 
after sym ptom  onse t .3,5,6,8 In several studies that have 
determ ined the com ponen ts  o f  treatm ent delay, pa­
tient decision tim e and hospital trea tm ent times each 
could  account for ^ 1  h o u r .14" 11 P rehospital initiation 
o f throm bolytic therapy m ight therefore provide the 
opportunity to treat a large proportion of patients 
within the first 2 hours o f  sym ptom  onset. Tw o trials 
o f  prehospital th rom boly tic  therapy dem onstrated 
significant reductions in tim e to treatm ent, although
mortality in the preho spi ta I_ and hospital groups was
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farction Triage and Intervention (M ITI) prehospital 
trial, time to treatm ent was reduced by 33 minutes 
in the prehospital group. In addition, patients treated 
< 7 0  minutes from  sym ptom  onset had lower mor­
tality, sm aller infarct size, and im proved left ventric­
ular function . 13 O ver the years, several studies re­
porting the long-term  influence o f thrombolytic 
therapy have been published . 14“ ,6 The purpose o f the 
current study was to determ ine w hether the benefits 
of very early treatm ent w ere sustained in the years 
after discharge from  the hospital.
METHODS
Patient population: All patients who called 91 1 and 
had chest pain w ere evaluated by the 15 param edic 
units in the Seattle m etropolitan area. Using a 
checklist with inclusion and exclusion criteria, par­
amedics gathered inform ation on the patients1 clini­
cal presentations. This inform ation enabled hospital- 
based physicians to determ ine w hether the patients 
were candidates for throm bolytic therapy. Patients 
w ere excluded from  participating in the trial for the 
follow ing reasons: ( I )  chest pain > 6  hours from 
sym ptom  onset, ( 2 )  age > 7 5  years, or (3 )  the pres­
ence o f com plicating illnesses that were considered 
to be contraindications for prehospital thrombolytic 
therapy. D etailed inform ation on the study protocol
© 1 9 9 6  by Excerpta Medica, Inc. 
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FIGURE 1. Cumulative survival curves for the prehospital and hospital groups. No statistically significant difference was observed (p
0.46).
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FtGURE 2. Event-free survival 
analysis of 360 randomized 
patients allocated to prehosph 
tal- or hospitaMnitiated throm­
bolytic therapy. There was no 
statistically significant differ­
ence between the groups (p -
0.42).
and criteria for patient selection have been pub­
lish ed .11,1^
Briefly, a 12-lead prehospital electrocardiogram  
was ob tained  in the subset o f  patients w ho satisfied 
the criteria for enrollm ent. T he final decision to ran­
dom ize the pa tien t was m ade by a physician in the 
em ergency  departm en t o f  I o f  6  param edic base hos­
pitals. P aram edics  used a standard verbal consent to 
enroll patients in to  the study. A fter enrollm ent, p a ­
tients w ere random ized  to receive aspirin and recom ­
binant tissue p lasm inogen activator either before or
after hospital arrival. Intravenous sodium heparin 
w as adm inistered to both patient groups at the time 
o f hospital arrival. After hospital discharge, 289 pa** 
dents underw ent radionuclide measurements o f in­
farct size and left ventricular ejection fraction.
Follow-up: To determine survival status and the 
need for readmission to the hospital for cardiac rea­
sons, m ail questionnaires were sent to patients an­
nually. Patients were queried concerning hospital ad­
m issions for the following reasons: ( 1 ) angiography, 
( 2 ) coronary angioplasty, ( 3 ) coronary artery bypass
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TABLE I Observed Cardiac-Related Events for Both Randomized Groups and the 
Subgroups
Number of Events
Number of Events/1 00 
Patients/Year
Prehospital Hospital Prehospital Hospital
Event (n = 175) (n -  185) (n = 175) Z3 11 00 Ln
»
p Valu
Angiography 54 70 11.5 13.8 0.37
Angioplasty 34 43 7.0 8.5 0.45
Bypass surgery 20 20 4.1 4.0 0.90
Congestive heart failure 12 13 2.6 2.5 0.94
Myocardial infarction 22 21 4.3 4.3 0.98
Recurrent ischemia 24 40 4.9 7.9 0.1 1
Total 166 207 34.2 41.0 0.28
treatm ent, d ichotom ized by a 70- 
m inute outpoint. S tepw ise Cox re­
gression analysis w as used to iden­
tify factors related  to long-term  
survival; variables were included in 
the m odel if  the p value for inclu­
sion was < 0 .0 5 . To com pare the 
num bers o f cardiac-related hospital 
adm issions, w e  calculated the aver- 
age num ber o f events per patient per 
follow -up year. B aseline character­
istics and clinical outcom es were 
com pared by the chi-square test for 
discrete variables and the t test for
surgery, (4 )  congestive heart failure, (5 )  chest pain, 
or ( 6 ) subsequent myocardial infarction. In addition 
to the mail questionnaires, hospita l adm ission logs 
were screened for cardiac-related adm issions. Infor­
mation about procedures and adm ission  and dis- 
charge diagnoses was also recorded. T elephone con­
tact w ith patients or surviving re la tives often enabled 
us to com plete missing inform ation. F inally, the N a­
tional Death Index was used to ascerta in  vital status 
for patients who were lost to fo llow -up.
Statistical methods: The prim ary  end  points of this 
study were survival and event-free survival, defined 
as survival free o f death, m yocard ia l infarction, or 
hospitalization for angina, congestive  heart failure, 
or revascularization. Survival analyses included 
deaths from all causes. Survival curves fo ra l i  groups 
were obtained according to the m ethod  o f  Kaplan 
and M eie r ,17 The log rank test w as used  to determ ine 
whether survival and event-free survival were dif­
ferent according to random ization group and time to
continuous varu 'S,
RESULTS
Of all 360 patients, 175 w ere random ized to re­
ceive prehospital-initiated throm bolytic therapy, and 
the other 185 w ere allocated to throm bolytic treat­
m ent after hospital arrival. B aseline  characteristics 
o f  these patients have been described .'-1 C ardiac his­
tories and hem odynam ic findings did not differ sig­
nificantly betw een the groups, and baseline electro­
cardiographic findings were also similar: Anterior 
infarction occurred in 39%  (p  =  0 .99) and inferior 
infarction in 58% (p =  0 .99) o f  both groups. Patients 
in the hospital group w ere slightly o lder than their 
counterparts (59  ±  1 0  years in the prehospital group 
vs 57 ±  10 years in the hospital group; p =  0 .04 ). 
T im e from  sym ptom  onset to treatm ent differed sig­
nificantly; the m edian tim e to treatm ent for the pre­
hospital group was 77 minutes (56  and 101; 25th 
and 75th percen tiles), and it w as 110 m inutes (85
FIGURE 3. Cumulative survival 
curves for patients treated very 
earl/ (<70 minutes) versus 
those treated later (70 minutes 
to 3 hours). The observed dif­
ference was not statistically 
significant (p » 0,12).
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FIGURE 4. Event-free survival 
analysis for patients treated 
very early (<70 minutes) ver­
sus those treated later (70 
minutes to 3 hours). The curves 
were similar (p = 0.80).
and 140; 25th and 75th percentiles) for the hospital
group (p  < 0 . 0 0 0 1  )'.
O verall, 336 patients received thrombolytic ther­
apy in e ither the  prehospital or the hospital setting; 
24 d id  not rece ive  throm bolytic treatment for varying 
rea so n s . 13 In nearly  25% (82 of 336) of the patients 
receiving throm bolytic  therapy, tim e from symptom 
onset to trea tm ent was < 7 0  minutes, M ost were 
treated la ter; 254  patients received thrômbolytic 
therapy betw een  70 minutes and 3 hours o f  symptom 
onset.
T he  baseline characteristics o f  patients treated 
early  ( < 7 0  m inu tes) and of those treated later were 
sim ilar. Patients in the early group were slightly 
younger, a lthough this difference was not statisti­
cally significant (56  ±  10 years in the early-treated 
patien ts  vs 58 ±  10 years in the later-treated patients; 
p — 0.051 ). T im e to treatm ent showed a distinct dif­
ference: T he m edian time to treatment was 55 
m inutes (4 9  and 63; 25th and 75th percentiles) for 
the early-treated  patients com pared with 104.5 
m inutes (85  and 141; 25th and 75th percentiles) for 
those w ho w ere treated later.
In the first year of follow-up, 31 patients died; 
inform ation  on cardiac-related events was available 
fo r 97%  o f  patients. W ith  the National Death Index 
and returned  follow -up letters, it was possible to as­
certain  vital status for all patients. Figure 1 shows 
cum ula tive  survival curves fo r the prehospital and 
hospital groups. There was no significant difference 
in long-term  survival betw een the groups; 2 -year sur­
vival w as 89%  fo r prehospital-treated patients and 
91%  fo r  those  treated in the hospital setting (p  =
0 .4 6 ) .  E ven t-free  survival also did not differ accord­
ing to random ization group (F igure  2 ) . Two years 
after enrollment, event-free survival was 56% and 
64% in the prehospital and hospital groups, respec­
tively (p  =  0 .42).
To determ ine w hether patients differed in the 
num ber o f cardiac-related  events, we calculated 
event rates for both groups (T ab le  I ) .  The prehos­
pital group show ed a slightly low er number o f  car­
diac-related adm issions (p  =  0 .2 8 ) . Overall, there 
was a difference o f 68  cardiac-related events per 
1,000 patients per year (T ab le  I ) .  Hospital read­
mission rates at 1 and 2  years of follow-up were 
also determ ined. For the prehospital group, 31% 
and 36%  of patients were rehospitalized at 1 and 2 
years, respectively. In the hospital group, 25%  of 
patients were readm itted at 1 year and 31% at 2 
years (p =  0 .6 5 ).
During the first year o f follow-up, 28 of 336 pa­
tients who received throm bolytic therapy died, In­
formation on cardiac-related events was available for 
96% of surviving patients. Figure 3 shows the long­
term survival for the group that was treated very 
early versus the group that received thrombolytic 
agents ^ 7 0  minutes from sym ptom  onset. Unad­
justed survival in the early-treatm ent group appeared 
to be improved, but the difference was not statisti­
cally significant, because the survival curves crossed 
after 3 years. Tw o-year survival was 98% for the 
early-treated patients and 8 8 % for those who re­
ceived thrombolytics later (p  =  0 . 1 2 ).
Figure 4 shows that there was no significant dif­
ference in event-free survival between the very early 
and the later-treated group. Event-free survival at 2 
years was 65% for the early group and 59% for the
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TABLE 11 Observed Cardiac-Related Events for Patients Treated Very Early and 
Those Treated Later
Number of Events
Number of Evonls/100 
Patients/Year
Even!
<70  min 
(n = 82)
2:70 min 
(n -  254)
< 7 0  min 
(n = 82)
«=70 min
(n -  254) p Valu
Angiography 27 89 11.0 13.1 0,45
Angioplasty 22 40 9.0 6.8 0.35
Bypass surgery 9 29 3.7 4.3 0.69
Congestive heart failure 4 19 1.6 2.8 0.38
Myocardial infarction 8 35 3.3 5.1 0,18
Recurrent ischemia 1 1 49 4.5 7.2 0,18
Total 81 267 33.0 39.2 0,35
to treatm ent o f  only 33 minutes, in­
stead o f  the expected tim e o f ^  I 
hour . 13 This, com bined with the
conservative selection criteria, and
later group (p  =  0 .80 ). Event rates were sim ilar in 
the 2  groups (Table  I I ) .  Readm ission rates at 1 and 
2  years o f follow-up were 30%  and 33% , respec­
tively, for the early-treated patients and 27%  and 
33% fo r those treated later. These differences were 
not statistically significant (p  =  0 .74).
To identify factors that were related to long-term  
survival, w e perform ed stepwise Cox m ultivariate  
regression analysis in 329 patients with com plete  in­
formation. A dvanced age, a history o f  heart failure, 
and bypass surgery perform ed before the index hos­
pitalization were associated with decreased survival. 
After adjustm ent for these variables, trea tm ent < 7 0  
m inutes from sym ptom  onset was no t associated 
with survival (p  =  0 .30 ). In addition, tim e to treat­
ment m easured as a continuous variable w as not p re ­
dictive of long-term  survival (p  =  0 .8 4 ).
DISCUSSION
T im e to treatment is an im portant pred ictor o f
11 «  a
hospital m ortality .3,8,1, The earlier throm bolytic treat­
ment is initiated, the more m yocardium  is saved and 
the better the clinical outcome, A ccording to this hy­
pothesis, outcom e would be best in patients treated 
very early. W e conducted this follow -up study to 
assess the long-term  influence o f very early initiation 
of throm bolytic therapy.
T here  was a trend toward im proved long-term  
survival after very early thrombolysis. T h is  benefit 
resulted primarily from a m uch more favorab le  in- 
hospital mortality rate for patients treated very early. 
M oreover, readm ission rates and event-free survival 
were not influenced by a substantial reduction  in 
time to treatment. Therefore, despite the m ajor im ­
pact o f  early treatm ent on short-term m ortality , the 
influence on long-term  clinical outcom e was less im ­
pressive. The benefits o f very early treatm ent are im ­
mediate; with the passage o f  time, other factors, in­
cluding age and gender, as well as the use  o f  aspirin, 
ß  blockers, risk factor reduction, or revascularization 
procedures, becom e preem inent for all patients.
Survival curves for the prehospital- and hospital- 
treated patients were similar. These findings may 
have been influenced by the unanticipated reduction 
of 40 minutes in hospital treatment tim es in this 
study . 13 Consequently, prehospital in itiation  of 
thrombolytic therapy resulted in a reduction in time
the relatively low patient numbers, 
might have prevented the difference 
betw een treatm ent groups that was 
expected.
In the analysis o f  early treatment, 
the earlier reported 30-day survival 
benefit for patients treated < 7 0  
minutes from  sym ptom  onset re­
sulted in m arkedly im proved sur­
vival in this group. This gain was 
caused prim arily by a low er num ber 
of in-hospital deaths for the early-treated patients. 
Considering the entire follow -up period, the ob­
served difference betw een curves was not statisti­
cally significant (p  =  0 ,1 2 ). In addition, results from 
Cox regression analysis indicated that early treat­
m ent was not associated with long-term  survival/ 
These findings do not suggest that very early treat­
m ent exerts an additional salutary effect that was re­
alized in the first m onth after treatment.
Event-free survival was not influenced by a re­
duction in tim e to treatment. R eadm ission  rates and 
event rates also did not differ significantly, The 
slightly higher event-free percentages in the very 
early-treated group w ere caused by the few er deaths 
in this group and not by a difference in hospital ad­
missions for cardiac events. T hese  findings do not 
support the hypothesis that early treatm ent w ould re­
sult in improved overall cardiac status and thus few er 
subsequent admissions. A  D utch study has suggested 
that freedom from reocclusion does result in im­
proved long-term event-free surv ival . 18
Follow-up in the M ITI prehospital throm bolysis 
trial demonstrated that short- and long-term  clinical 
outcomes were sim ilar for prehospital- and hospital- 
treated patients. Thirty-day survival was improved 
with very early throm bolytic therapy, but very early 
treatment did not decrease either subsequent survival 
or the num ber of cardiac events after hospital dis­
charge.
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